FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 340:1115-1117 April 8, 1999 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Shepherd, J. Related Article by The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Related Article by Gottlieb, S. S. PubMed Citation

To the Editor: The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) trial (Nov. 5 issue)¹ is the third study, after the Scandinavian Simvastatin Survival Study² and the Cholesterol and Recurrent Events study,³ on the use of 3-hydroxy-3-methylglutaryl–coenzyme A reductase inhibitors for secondary prevention of coronary disease. The positive results of this trial are as marginal as those of the studies that preceded it.

The authors calculated relatively high values for risk reduction with pravastatin as compared with placebo, those being between 11 and 23 percent, which might tempt the inexperienced physician to use statins universally. The relevant values with . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Flower, J., Dreifus, L. S., Bove, A. A., Weintraub, W. S. (2000). Technological advances and the next 50 years of cardiology. J Am Coll Cardiol 35: 81B-90B  
• Flower, J., Dreifus, L. S., Bove, A. A., Weintraub, W. S. (2000). Technological advances and the next 50 years of cardiology. J Am Coll Cardiol 35: 1082-1091 [Full Text]